The metabolic change promotes membrane localization of the costimulatory molecule OX40L in a lipid modification-dependent manner, leading to CD8+ T cell activation in HCC and improving anti-PD-1 therapy efficacy. Here, CD8A is linked to hepatocellular carcinoma.